Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Lutzky

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Seminars in Cutaneous Medicine and Surgery|February 1, 2011
New therapeutic options in the medical management of advanced melanomaJose Lutzky
Chinese Clinical Oncology|April 6, 2015
Checkpoint inhibitors in the treatment of cutaneous malignant melanomaJose Lutzky
Expert Opinion on Biological Therapy|April 7, 2010
Velimogene aliplasmidHeloisa P Soares, Jose Lutzky
Cancer Management and Research|January 30, 2015
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal diseaseLudimila Cavalcante, Asim Amin, Jose Lutzky
Surgical Oncology Clinics of North America|March 28, 2026
Contemporary Management of Immune Checkpoint Inhibitor-related Adverse EventsAkshee Batra, Daniel Tuerff, Jose Lutzky
Pigment Cell & Melanoma Research|May 31, 2008
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationJose Lutzky, Juergen Bauer, Boris C Bastian
Melanoma Research|July 22, 2005
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patientsJohn B Alexis, Antonio E Martinez, Jose Lutzky
BMJ Case Reports|July 20, 2022
Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neckJoel Grunhut, Shimron Brown, Jose Lutzky, et al.
Journal for Immunotherapy of Cancer|March 28, 2017
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)Jeanelle King, Javier de la Cruz, Jose Lutzky
Seminars in Oncology|October 31, 2002
Antibody-based vaccines for the treatment of melanomaJose Lutzky, Ana M Gonzalez-Angulo, Jennifer A Orzano
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Seminars in Cutaneous Medicine and Surgery|February 1, 2011
New therapeutic options in the medical management of advanced melanomaJose Lutzky
Chinese Clinical Oncology|April 6, 2015
Checkpoint inhibitors in the treatment of cutaneous malignant melanomaJose Lutzky
Expert Opinion on Biological Therapy|April 7, 2010
Velimogene aliplasmidHeloisa P Soares, Jose Lutzky
Cancer Management and Research|January 30, 2015
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal diseaseLudimila Cavalcante, Asim Amin, Jose Lutzky
Surgical Oncology Clinics of North America|March 28, 2026
Contemporary Management of Immune Checkpoint Inhibitor-related Adverse EventsAkshee Batra, Daniel Tuerff, Jose Lutzky
Pigment Cell & Melanoma Research|May 31, 2008
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationJose Lutzky, Juergen Bauer, Boris C Bastian
Melanoma Research|July 22, 2005
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patientsJohn B Alexis, Antonio E Martinez, Jose Lutzky
BMJ Case Reports|July 20, 2022
Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neckJoel Grunhut, Shimron Brown, Jose Lutzky, et al.
Journal for Immunotherapy of Cancer|March 28, 2017
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)Jeanelle King, Javier de la Cruz, Jose Lutzky
Seminars in Oncology|October 31, 2002
Antibody-based vaccines for the treatment of melanomaJose Lutzky, Ana M Gonzalez-Angulo, Jennifer A Orzano
Pageof 7